$0.60
+0.03 (+5.16%)
Open$0.60
Previous Close$0.57
Day High$0.61
Day Low$0.59
52W High$5.14
52W Low$0.43
Volume—
Avg Volume422.5K
Market Cap23.23M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Sell
10 analysts
Price Target
+8,131.3% upside
Current
$0.60
$0.60
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 648.8K | 854.4K | 9.03M |
| Net Income | -68,814,722 | -81,566,244 | 1.99M |
| Profit Margin | -10,579.8% | -10,050.9% | 22.0% |
| EBITDA | -74,703,210 | -93,465,098 | 3.04M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -24.1% | -24.1% | +1.4% |
| Debt/Equity | — | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |